Cryoport and BioLife Cellular Therapy Services, part of the global biopharma company, Takeda Pharmaceutical Company, have joined forces in a strategic relationship to establish an integrated supply chain platform to offer standardized cell therapy collection, processing, storage, and distribution services. The platform will provide consistent, high-quality cellular starting material for use in the manufacture of life-saving cellular therapies. The relationship aims to shorten processing & logistics time and standardize collections to accelerate cell therapy programs.
Cryoport Systems is the market leader in integrated temperature-controlled supply chain solutions for critical, irreplaceable products and materials in the life sciences industry. We are already trusted to support over 650 active clinical trials and leading commercial products worldwide - delivering unparalleled supply chain services for products, therapies and treatments requiring specialized temperature-controlled management. And, as the life sciences constantly evolve and advance, so do we.